Financial Performance - The company's revenue for Q1 2023 was CNY 833,267,364.92, representing a 27.04% increase compared to CNY 655,889,746.24 in the same period last year[3] - Net profit attributable to shareholders reached CNY 171,990,894.69, a significant increase of 345.34% from CNY 38,620,485.08 year-on-year[3] - Basic and diluted earnings per share were both CNY 0.1074, reflecting a 345.64% increase from CNY 0.0241 in the same quarter last year[3] - Net profit for Q1 2023 was CNY 198.30 million, compared to CNY 66.75 million in Q1 2022, representing a 197% increase[36] - The company reported a significant increase in other income to CNY 51.70 million, up from CNY 35.07 million year-over-year[36] Cash Flow - The net cash flow from operating activities surged to CNY 203,200,253.08, marking a 1,922.82% increase compared to CNY 10,045,400.08 in the previous year[3] - The total cash inflow from operating activities for Q1 2023 was CNY 1,034,934,922.93, an increase of 29.5% compared to CNY 798,255,462.52 in the same period last year[37] - Cash outflow for purchasing goods and services was CNY 611,308,050.26, compared to CNY 525,568,731.34 in the previous year, reflecting a 16.3% increase[37] - The net cash flow from investing activities was CNY -249,330,788.58, compared to CNY -163,613,955.67 in Q1 2022, indicating increased investment expenditures[37] - The net cash flow from financing activities was CNY 6,041,070.23, a significant decrease from CNY 484,630,487.20 in the same quarter last year[38] Assets and Liabilities - Total assets at the end of the reporting period were CNY 15,434,647,225.18, a 0.70% increase from CNY 15,327,991,128.58 at the end of the previous year[3] - The company's current assets totaled RMB 8,875,468,146.88, a decrease from RMB 8,948,462,792.55 at the beginning of the year, indicating a decline of about 0.81%[33] - The total liabilities decreased to RMB 3,337,105,308.88 from RMB 3,508,790,853.95, marking a reduction of approximately 4.88%[33] - Total equity increased to CNY 11.19 billion, up from CNY 10.99 billion in the previous year[34] Shareholder Information - The total number of common shareholders at the end of the reporting period was 128,635[13] - Liu Junhui, the largest shareholder, holds 3.65% of the shares, totaling 58,714,766 shares[13] - The company has a total of 48,798,228.00 restricted shares at the beginning of the period, with 9,031,471.00 shares released during the period[15] - The company is actively managing its shareholder structure, with several shareholders involved in margin trading[14] Research and Development - Research and development expenses increased to CNY 178.91 million, up 28.5% from CNY 139.11 million in the same quarter last year[35] - The company is advancing the Phase III clinical trials for the ACYW135 meningococcal polysaccharide conjugate vaccine and the nine-valent HPV vaccine, with the latter's clinical research proceeding as planned[17] - The company aims to achieve conditional approval for the new COVID-19 variant mRNA vaccine, with Phase III clinical research nearing completion[17] Market Expansion and Product Development - The company is actively pursuing international market expansion, with ongoing registration projects in multiple countries to promote high-quality development of international business[18] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[36] - The company has received procurement orders for the A group and C group meningococcal polysaccharide vaccine from Egypt for its Expanded Program on Immunization (EPI)[18] Stock Options and Share Repurchase - The company granted a total of 2.25 million stock options in the first quarter of 2023, with 170,000 options granted to three departing employees[23] - The company plans to repurchase between 2 million and 4 million shares at a maximum price of RMB 50 per share, with an estimated total repurchase amount not exceeding RMB 200 million[19] - As of the report date, the company has repurchased 2,000,000 shares, accounting for 0.12% of the total share capital, with a total transaction amount of approximately RMB 72.2 million[19]

证券代码：300142 证券简称：沃森生物 云南沃森生物技术股份有限公司投资者关系活动记录表 编号：2023-005 | | □ 特定对象调研 □ 分析师会议 | | | --- | --- | --- | | 投资者关系活动 | □ 媒体采访 √ 业绩说明会 | | | 类别 | 新闻发布会 □ 路演活动 □ | | | | □ 现场参观 | | | | 其他（ ） □ | | | 参与单位名称及 | | | | 人员姓名 | 投资者网上提问 | | | 时间 | 2023 年 4 月 12 日（星期三）15:00-17:00 | | | 地点 | 公司通过全景网"全景•路演天下"（https://rs.p5w.net）采用网 | | | | 络远程的方式召开 2022 年度业绩说明会 | | | | 董事长 李云春 | | | | 董事、总裁 姜润生 | | | 上市公司接待人 | 独立董事 朱锦余 | | | 员姓名 | 财务总监 周华 | | | | 投资总监 赵金龙 | | | | 董事会秘书 刘宇然 | | | | 2023 年 4 月 12 日 15:00-17:00，公司通过全景网"全景•路演 ...

Financial Performance - The total revenue for 2022 was 1.5 billion CNY, representing a year-on-year increase of 15%[3]. - The company achieved a net profit of 300 million CNY in 2022, up 20% compared to the previous year[3]. - The company's operating revenue for 2022 was ¥5,086,445,195.10, representing a 46.89% increase compared to ¥3,462,831,094.14 in 2021[12]. - The net profit attributable to shareholders for 2022 was ¥728,652,009.34, a 70.35% increase from ¥427,747,681.59 in 2021[12]. - The net profit after deducting non-recurring gains and losses was ¥859,124,544.51, up 45.33% from ¥591,146,772.49 in 2021[12]. - The basic earnings per share for 2022 was ¥0.4546, a 66.70% increase from ¥0.2727 in 2021[12]. - The cash flow from operating activities for 2022 was ¥1,201,491,008.09, a 70.36% increase from ¥705,276,750.42 in 2021[12]. - The company reported a quarterly revenue of ¥1,692,153,912.48 in Q2 2022, which was the highest among the four quarters[14]. - The company reported a total revenue of ¥1.86 billion from its subsidiary Guangzhou Watson, with a net profit of approximately ¥62.64 million[94]. - The company reported a total shareholding of 63,005,970 shares at the end of the reporting period, with a net decrease of 10,608,625 shares due to various transactions[115]. Market Expansion and Product Development - User data indicated a 25% increase in vaccine sales volume, with a total of 10 million doses sold in 2022[3]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by 2025[3]. - New product development includes a novel mRNA vaccine, expected to enter clinical trials in Q3 2023[3]. - Future guidance estimates a revenue growth of 20% for 2023, driven by new product launches and market expansion[3]. - The company is actively pursuing internationalization and import substitution strategies to enhance its market presence[31]. - The company aims to accelerate the development of new vaccines, including mRNA vaccines for COVID-19 variants and a nine-valent HPV vaccine, to meet market demand[98]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[126]. - The company is committed to a comprehensive internationalization strategy, aiming to complete WHO pre-certification for key products and expand into international markets[98]. Research and Development - The company is exploring strategic acquisitions to enhance its R&D capabilities, with a budget of 500 million CNY allocated for this purpose[3]. - The company’s R&D efforts include multiple vaccines in various clinical stages, including the nine-valent HPV vaccine and the new mRNA vaccines for COVID-19[36]. - The company has a stable R&D team with over 210 employees holding doctoral or master's degrees, enhancing its innovation capabilities[46]. - The company is committed to building a smart factory through digital integration of production quality management and cold chain logistics monitoring[39]. - The company has established a modern vaccine production base in Yuxi, Yunnan, capable of large-scale production of multiple vaccine varieties, adhering to WHO PQ pre-certification standards[46]. - The company is actively involved in the research and development of new products, particularly in the vaccine sector[120]. Financial Management and Investments - The company has received government subsidies amounting to ¥111,110,270.61 in 2022, which was an increase compared to ¥71,773,119.15 in 2021[18]. - The company has made significant equity investments, including ¥100 million in Shanghai Zerun Biotechnology Co., holding a 56.61% stake, and ¥50 million in Guangzhou Watson Health Technology Co., acquiring a 100% stake[75]. - The total investment amount for the reporting period was ¥660 million, a decrease of 60.23% compared to ¥1.66 billion in the same period last year[74]. - The company has a long-term commitment to avoid related transactions with Watson Bio after the completion of the asset restructuring[192]. - The company has a commitment to ensure that any future stock incentive plans are linked to the execution of its compensation measures[193]. Corporate Governance and Compliance - The company has established a comprehensive quality management system to ensure the delivery of qualified, safe, and effective drugs to end users, adhering to various regulations such as the Drug Administration Law and Vaccine Management Law[101]. - The company has implemented strict anti-fraud, anti-money laundering, and anti-bribery management systems to mitigate compliance risks[169]. - The company has established a risk management department in its subsidiary to identify, prevent, and control risks in the production and quality management processes, implementing risk-based management throughout the production process[102]. - The company has maintained a stable governance structure, ensuring that shareholders, especially minority shareholders, can exercise their rights effectively[104]. - The company has a dispersed shareholding structure, with no single shareholder able to control the board or the company[109]. Environmental Responsibility - The company has implemented a series of environmental protection projects, including the mRNA COVID-19 vaccine industrialization project, which received approval in August 2021 and passed environmental acceptance in November 2022[177]. - The company has established pollution control facilities, including one wastewater treatment facility and two air pollution control facilities, all of which are operating normally[179]. - The company is committed to maintaining compliance with environmental regulations and enhancing corporate governance to protect shareholder interests, particularly for minority shareholders[175]. - The company has received multiple environmental impact assessment approvals for various projects, ensuring compliance with local environmental regulations[177]. - The company aims to create a production system with minimal environmental impact, promoting green and low-carbon development[185]. Shareholder Relations and Communication - The company emphasizes the importance of maintaining investor relations and has adhered to its investor relations management system throughout the reporting period[106]. - The company conducted a performance online briefing on April 6, 2022, to enhance investor understanding of its development strategy and operational management[106]. - The company maintains regular communication with investors through various channels, ensuring timely responses to inquiries[108]. - The company has established designated media for information disclosure, ensuring equal access to information for all shareholders[108]. - The company held its 2021 Annual General Meeting on April 12, 2022, with an investor participation rate of 18.67%[111]. Employee Management and Development - The total number of employees at the end of the reporting period was 2,249, with 1,602 in production roles[141]. - The company has implemented a new performance management system in 2022 to enhance the connection between organizational and individual performance results[143]. - The company has established a talent management project, establishing 6 talent standard models to optimize its talent management system[145]. - The company has expanded its training programs to include a wider range of participants, enhancing understanding of compliance and operational standards among subsidiary staff[175]. - The company has implemented employee stock ownership and stock option incentive plans to enhance talent retention and organizational cohesion[143].

证券代码：300142 证券简称：沃森生物 公告编号：2023-027 二〇二三年三月三十日 关于举行2022年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 云南沃森生物技术股份有限公司（以下简称"公司"）《2022年年度报告》 已于2023年3月30日披露，为使投资者进一步了解公司的财务状况、经营情况及 公司发展规划，公司将于2023年4月12日（星期三）下午15:00-17:00在全景网举 行2022年度业绩网上说明会，本次说明会将采用网络远程方式举行，投资者可登 陆全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次业绩说明会。 出席本次业绩说明会的人员有：公司董事长李云春先生，董事、总裁姜润生 先生，独立董事朱锦余先生，财务总监周华女士，董事会秘书刘宇然先生和投资 总监赵金龙先生。 为充分尊重投资者，提高交流的针对性，现就公司 2022 年度业绩网上说明 会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 11 日（星期二）12:00 前访问 https://ir. ...

Group 1: Vaccine Development and Sales Expectations - The company is optimistic about the sales growth of its bivalent HPV vaccine and 13-valent pneumonia combined vaccine, with expectations based on market competition and promotional progress [1] - The bivalent HPV vaccine was launched in 2022, contributing a full accounting year's performance in 2023 [1] - The 13-valent pneumonia combined vaccine's market competition landscape is clear, and the company is expanding both domestic and international markets [1] Group 2: Clinical Trials and Research - The phase III clinical trial for the new COVID-19 variant mRNA vaccine in collaboration with Bluebird Bio has completed participant enrollment and will proceed according to regulatory requirements [1] - The company has completed participant enrollment for the phase III clinical trial comparing the immunogenicity of its 9-valent HPV vaccine with Gardasil 9, with subsequent work on schedule [2] Group 3: Market Trends and Challenges - The declining birth rate in recent years may impact sales of the bivalent HPV vaccine and 13-valent pneumonia combined vaccine, but the company remains confident in its core products [2] - The company is closely monitoring national policies encouraging childbirth, believing that the effects will gradually manifest [2] Group 4: New Initiatives - The Yunnan Vaccine Laboratory (under construction) aims to integrate resources from leading biopharmaceutical industries in Yunnan, enhancing research and development capabilities [2] - The company is committed to ensuring product supply for the 23-valent pneumonia polysaccharide vaccine, which has seen increased sales due to heightened awareness of its protective role against bacterial pneumonia [2]

Group 1: Market Outlook and Growth Potential - The company maintains an optimistic outlook for the performance growth of the 13-valent pneumonia conjugate vaccine, anticipating increased demand due to policies encouraging childbirth and the return to normal vaccination rates post-pandemic [1] - The domestic market penetration of the pneumonia conjugate vaccine has not yet reached its ceiling, indicating further growth opportunities, especially in urban markets [1] - The company is actively seeking international market opportunities, focusing on countries with high population growth and good financial conditions, particularly in Southeast Asia, the Middle East, North Africa, and South America [2] Group 2: Sales and Distribution Challenges - The sales of the 23-valent pneumonia polysaccharide vaccine have been sluggish due to the impact of the COVID-19 pandemic on routine vaccinations and government procurement [2] - There have been reports of vaccine stock shortages at some vaccination points, attributed to delays in procurement and distribution caused by pandemic control measures [2] - The company is committed to promoting the importance of the pneumonia vaccine for high-risk groups, particularly the elderly, through academic promotion and consumer education [2] Group 3: International Expansion and Procurement - The company is focusing on expanding its international market presence, with plans to engage in bulk procurement through international organizations like UNICEF and Gavi, contingent on WHO prequalification [2] - The 13-valent pneumonia conjugate vaccine received registration in Morocco in 2022, with ongoing technical transfer work in Morocco and India [2] - The company aims to balance production capacity to meet both domestic and international market demands while ensuring shareholder interests [2] Group 4: Pricing Strategy and Market Position - The pricing strategy for the dual-valent HPV vaccine is designed to remain stable, with adjustments based on tender quantities and competitive conditions in different provinces [3] - The company has completed the necessary upgrades for the quadrivalent meningococcal vaccine and is preparing documentation for further certification [2] - The dual-valent HPV vaccine launched in 2022 is currently in a supply-demand imbalance, with many regions experiencing shortages [3] Group 5: Research and Development Investment - The company plans to maintain reasonable and continuous investment in innovation and product development, focusing on mRNA technology platforms [3] - Future R&D efforts will prioritize product iteration and key pipeline development, aligning with the company's growth strategy [3] - The company believes that sustained investment in cutting-edge technology and innovative research will enhance its competitive position in the market [3]